DataMEDS AI Releases CEO Letter
Key Highlights
- ➤DataMEDS (MEDS) outlines Q4 2026 focus on GLP-1 patient management and healthcare cost reduction
- ➤Florida HMO partnered with DataMEDS on its Health Lives Here patient-management initiative
- ➤Helomics acquisition expands DataMEDS into cancer diagnostics and healthcare AI applications
- ➤5,724,857 common shares outstanding; 2,745,900 shares deposited at DTCC available for trading
- ➤80,826 cash warrants remain exercisable at a fixed $35.00 per share
Expert Statements
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“The reality is healthcare in America is broken. To fix it, the focus must go back towards helping the patient, insured or uninsured, who ends up subsidizing the costs.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“Our business model is rooted in cutting out the middleman so that the payor not only pays a fair price, but more importantly receives beneficial health outcomes as a result.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“DataMEDS' objective is to narrow the arbitrage between what you are paying for and what you are getting.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“To accomplish this daunting task in the face of heavily entrenched and overcompensated stakeholders, we must leverage patients' data to rein in the army of middlemen gouging the industry.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“To the extent we can do that efficiently, initially in GLP-1 patient management - one of the most expensive pockets of the healthcare ecosystem - we believe we can simultaneously improve outcomes while reducing costs by improving regimen compliance, managing the process of titrating up as therapy is initiated and titrating down as the need for therapeutic intervention lessens, by seamlessly helping to improve patient behavior and providing the right support products at the right time to help manage side effects and helping physicians more efficiently monitor their patients leveraging our technology and intellectual property assets.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“This is exactly why a Florida-based Health Maintenance Organization (HMO) decided to work with DataMEDS around our Health Lives Here initiative to implement a formulaic process around helping their members manage their health journey.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“To the extent that we are successful in providing insights that prove useful and deliver better outcomes, lower costs or both, we will have proven a very scalable business model that will allow us to capture more and more institutional payors that see tremendous potential value in our approach and understand that trying to achieve this objective using competitors' platforms violates our healthcare technology intellectual property.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“Our physical healthcare infrastructure, which leverages our own pharmacy, lab and telemedicine platforms together with our proprietary independent pharmacy network, allows us to view the different aspects of the healthcare journey through a common lens that creates synergistic revenue streams with each patient interaction.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“This reduces our reliance on achieving maximum per interaction revenue to instead focus on long-term repeat customers that view our services as a better alternative to their current treatment options, and less risky from an intellectual property litigation standpoint.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“The recent acquisition of Helomics underscores our vision to improve outcomes while reducing costs.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“To accomplish this objective for the benefit of shareholders, we must create synergies using approaches that may appear disjointed at first glance.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“For example, we must conduct research and development (R&D), however we must do so profitably by increasing patient flow through our healthcare delivery portals and compliantly leveraging that patient base to create new data inputs that can be used to deliver measurable benefit outputs in the future.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“We know that most patients are willing to allow their data to be used in a de-identified way to help improve treatment paradigms.”
Gerald Commissiong, Interim Co-CEO of DataMEDS AI
“As we work to complete the turnaround that began in the second quarter, we are focused on delivering value to patients, organizations that manage patients and shareholders.”
TAMPA, FL / ACCESS Newswire / November 16, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or("DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today provided a fourth quarter 2026 corporate outlook from its Interim Co-CEO Gerald Commissiong:
"The reality is healthcare in America is broken. To fix it, the focus must go back towards helping the patient, insured or uninsured, who ends up subsidizing the costs. Our business model is rooted in cutting out the middleman so that the payor not only pays a fair price, but more importantly receives beneficial health outcomes as a result. DataMEDS' objective is to narrow the arbitrage between what you are paying for and what you are getting.
Get started
Create a free account to read the full story.
